Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Recipients of first kidney transplant
You may not be if
Those at high risk for acute allograft rejection, including those who receive a second or more renal transplant, those with a history of panel reactive antibody levels \>20%, and those considered by investigators to be at relatively higher risk for acute rejection
Human leukocyte antigen-identical donor-recipient pairs
Cold ischemia time \>36 hours (donor kidney)
Participants who are positive for hepatitis C antibody, on polymerase chain reaction, for hepatitis B surface antigen, and for human immunodeficiency virus
A positive purified protein derivative tuberculosis test (test performed within 1 year of enrollment), unless previously vaccinated with Bacille-Calmette-Guérin or those who had a history of adequate chemoprophylaxis
Any active infection that would normally exclude transplantation
Recipients of multiple organ transplants
Donor age \>60 or \<6 years or donors whose hearts were not beating
Recipients with underlying renal disease of (due to risk of rapid disease recurrence in the allograft): focal segmental glomerulosclerosis, Type I or II membranoproliferative glomerulonephritis, or hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura
A positive T-cell lymphocytoxic crossmatch using donor lymphocytes and recipient serum
A history of true allergy to intravenous iodinated roentgenographic contrast agents
Participants with life expectancy severely limited by disease state or other underlying medical condition
A history of cancer (other than nonmelanoma skin cell cancers cured by local resection) within the last 5 years
Mammogram film with any clinically significant abnormality requiring further investigation or biopsies
History of substance abuse (drug or alcohol) or psychotic disorders that were not compatible with adequate study follow-up
A currently functioning, nonrenal transplant
Previous treatment with basiliximab for any reason
Active peptic ulcer disease, chronic diarrhea, or gastrointestinal malabsorption
Those who had used any investigational drug within 30 days before the Day 1 visit.
Clareo Health | Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
